TY - JOUR
T1 - The application of digital health to the assessment and treatment of substance use disorders
T2 - The past, current, and future role of the National Drug Abuse Treatment Clinical Trials Network
AU - Marsch, Lisa A.
AU - Campbell, Aimee
AU - Campbell, Cynthia
AU - Chen, Ching Hua
AU - Ertin, Emre
AU - Ghitza, Udi
AU - Lambert-Harris, Chantal
AU - Hassanpour, Saeed
AU - Holtyn, August F.
AU - Hser, Yih Ing
AU - Jacobs, Petra
AU - Klausner, Jeffrey D.
AU - Lemley, Shea
AU - Kotz, David
AU - Meier, Andrea
AU - McLeman, Bethany
AU - McNeely, Jennifer
AU - Mishra, Varun
AU - Mooney, Larissa
AU - Nunes, Edward
AU - Stafylis, Chrysovalantis
AU - Stanger, Catherine
AU - Saunders, Elizabeth
AU - Subramaniam, Geetha
AU - Young, Sean
N1 - Funding Information:
Research reported in this publication was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Numbers UG1DA040309 and P30DA029926. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. LAM is affiliated with Pear Therapeutics, HealthSim, LLC, and Square2 Systems, Inc. Conflicts of interest are extensively managed by her academic institution, Dartmouth College.
Funding Information:
Research reported in this publication was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Numbers UG1DA040309 and P30DA029926 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/3
Y1 - 2020/3
N2 - The application of digital technologies to better assess, understand, and treat substance use disorders (SUDs) is a particularly promising and vibrant area of scientific research. The National Drug Abuse Treatment Clinical Trials Network (CTN), launched in 1999 by the U.S. National Institute on Drug Abuse, has supported a growing line of research that leverages digital technologies to glean new insights into SUDs and provide science-based therapeutic tools to a diverse array of persons with SUDs. This manuscript provides an overview of the breadth and impact of research conducted in the realm of digital health within the CTN. This work has included the CTN's efforts to systematically embed digital screeners for SUDs into general medical settings to impact care models across the nation. This work has also included a pivotal multi-site clinical trial conducted on the CTN platform, whose data led to the very first “prescription digital therapeutic” authorized by the U.S. Food and Drug Administration (FDA) for the treatment of SUDs. Further CTN research includes the study of telehealth to increase capacity for science-based SUD treatment in rural and under-resourced communities. In addition, the CTN has supported an assessment of the feasibility of detecting cocaine-taking behavior via smartwatch sensing. And, the CTN has supported the conduct of clinical trials entirely online (including the recruitment of national and hard-to-reach/under-served participant samples online, with remote intervention delivery and data collection). Further, the CTN is supporting innovative work focused on the use of digital health technologies and data analytics to identify digital biomarkers and understand the clinical trajectories of individuals receiving medications for opioid use disorder (OUD). This manuscript concludes by outlining the many potential future opportunities to leverage the unique national CTN research network to scale-up the science on digital health to examine optimal strategies to increase the reach of science-based SUD service delivery models both within and outside of healthcare.
AB - The application of digital technologies to better assess, understand, and treat substance use disorders (SUDs) is a particularly promising and vibrant area of scientific research. The National Drug Abuse Treatment Clinical Trials Network (CTN), launched in 1999 by the U.S. National Institute on Drug Abuse, has supported a growing line of research that leverages digital technologies to glean new insights into SUDs and provide science-based therapeutic tools to a diverse array of persons with SUDs. This manuscript provides an overview of the breadth and impact of research conducted in the realm of digital health within the CTN. This work has included the CTN's efforts to systematically embed digital screeners for SUDs into general medical settings to impact care models across the nation. This work has also included a pivotal multi-site clinical trial conducted on the CTN platform, whose data led to the very first “prescription digital therapeutic” authorized by the U.S. Food and Drug Administration (FDA) for the treatment of SUDs. Further CTN research includes the study of telehealth to increase capacity for science-based SUD treatment in rural and under-resourced communities. In addition, the CTN has supported an assessment of the feasibility of detecting cocaine-taking behavior via smartwatch sensing. And, the CTN has supported the conduct of clinical trials entirely online (including the recruitment of national and hard-to-reach/under-served participant samples online, with remote intervention delivery and data collection). Further, the CTN is supporting innovative work focused on the use of digital health technologies and data analytics to identify digital biomarkers and understand the clinical trajectories of individuals receiving medications for opioid use disorder (OUD). This manuscript concludes by outlining the many potential future opportunities to leverage the unique national CTN research network to scale-up the science on digital health to examine optimal strategies to increase the reach of science-based SUD service delivery models both within and outside of healthcare.
UR - http://www.scopus.com/inward/record.url?scp=85081998388&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081998388&partnerID=8YFLogxK
U2 - 10.1016/j.jsat.2020.02.005
DO - 10.1016/j.jsat.2020.02.005
M3 - Article
C2 - 32220409
AN - SCOPUS:85081998388
SN - 0740-5472
VL - 112
SP - 4
EP - 11
JO - Journal of Substance Abuse Treatment
JF - Journal of Substance Abuse Treatment
ER -